SCHEMBL5380212

SCHEMBL5380212

CC1(C)OC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)O1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
KDM4C Q9H3R0 1/20 0.50
MMP2 P08253 1/20 0.46
MMP13 P45452 1/20 0.46
GLA P06280 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TP53 P04637 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
MAOB P27338 3/20 0.44
LMNA P02545 2/20 0.44
GRM2 Q14416 1/20 0.44
FAAH O00519 1/20 0.43
MGLL Q99685 1/20 0.43
GSTP1 P09211 1/20 0.43
PPARG P37231 1/20 0.42
BCHE P06276 1/20 0.42
ALOX5 P09917 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3994040 1.00 MEN1 (0.50) MEN1KMT2AKDM4CMMP2MMP13
SCHEMBL3524746 0.86 GLA (0.43) GLANPSR1
SCHEMBL3524748 0.86 GLA (0.43) GLANPSR1
SCHEMBL3103917 0.84 GLA (0.66) MEN1KMT2AKDM4CMMP2MMP13
SCHEMBL13804959 0.82 POLB (0.48) KMT2AKDM4CMMP2GLANPSR1
SCHEMBL3990482 0.78 GLA (0.44) GLANPSR1LMNAPPARG
SCHEMBL5385235 0.78 GLA (0.44) GLANPSR1LMNAPPARG
SCHEMBL5800028 0.75 ALOX5 (0.52) MMP2MMP13MAOBGRM2FAAH
SCHEMBL13538515 0.74 MEN1 (0.50) MEN1KMT2AKDM4CMMP2MMP13
SCHEMBL13538534 0.74 MEN1 (0.50) MEN1KMT2AKDM4CMMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544812-B2 For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus ELI LILLY AND COMPANY (US) 2009-06-09 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY AND COMPANY 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors NCOA4, PPARG, PPARA MEN1 4860/4885KMT2A 2887/4885KDM4C 1371/4885
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA MEN1 4857/4885KMT2A 2642/4885KDM4C 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.